First-Line Atezolizumab OK'd for SCLC

In mid-March, the FDA approved the PD-L1 inhibitor atezolizumab in combination with carboplatin and etoposide as a first-line therapy for small cell lung cancer. The approval was based on results from the phase III IMpower133 trial in which adding atezolizumab to chemotherapy extended overall and progression-free survival.